Αποτελέσματα Αναζήτησης
3 Οκτ 2011 · The phase III, randomized, placebo-controlled Sequential Tarceva in Unresectable NSCLC (SATURN; BO18192) study evaluated maintenance erlotinib in patients with nonprogressive disease following first-line platinum-doublet chemotherapy.
The Sequential Tarceva in Unresectable NSCLC (SATURN) trial was designed to investigate the effectiveness of maintenance erlotinib treatment until the time of progression, with the goal of prolonging overall survival and delaying disease progression .
The Sequential Tarceva in Unresectable NSCLC (SATURN) study investigated the use of maintenance erlotinib following the completion of first-line chemotherapy. It demonstrated a significant improvement in overall survival from 11.1 months in the placebo group to 12.3 months in patients receiving maintenance erlotinib, with the important caveat ...
20 Δεκ 2010 · Recently, Cappuzzo et al Citation 50 presented data from the Sequential Tarceva in Unresectable NSCLC (SATURN) trial a double-blind, randomized, phase III study of maintenance erlotinib vs placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. The final results of the study found that the ...
20 Μαΐ 2010 · We designed the phase 3, placebo-controlled Sequential Tarceva in Unresectable NSCLC (SATURN; BO18192) study to assess use of erlotinib as maintenance therapy in patients with non-progressive disease following first-line platinum-doublet chemotherapy.
1 Οκτ 2010 · The importance of EGFR in tumor growth and progression has been demonstrated in clinical trials where EGFR inhibition has led to improved efficacy outcomes in patients with non-small cell lung cancer (NSCLC).
The global phase III SequentiAl Tarceva in UnResectable NSCLC (SATURN) study evaluated the efficacy and safety of the epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib as maintenance treatment in NSCLC patients without progression after first-line chemotherapy.
